Clinical trial PHERGain
Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: FDG-PET response-adapted strategy. The PHERGain study
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Non |
| Sponsor | MedSir |
| EudraCT Identifier | 2016-002676-27 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03161353 |
| Inclusion criteria | HER 2 positive first line |
| Last update |